Supplemental Online Content

Nam HS, Kim YD, Heo J, et al; OPTIMAL-BP Trial Investigators. Intensive vs conventional blood pressure lowering after endovascular thrombectomy in acute ischemic stroke. *JAMA*. Published September 5, 2023. doi:10.1001/jama.2023.14590

eTable 1. Inclusion and Exclusion Criteria

eTable 2. Demographic and Clinical Characteristics in Intention-to-Treat Analysis

- eTable 3. Changes of Blood Pressure Between Groups
- eTable 4. Primary and Secondary Outcomes in Per-Protocol Analysis
- eTable 5. Imaging Findings
- eTable 6. Post Hoc Sensitivity Analysis Considering Enrollment Site

eFigure 1. Prespecified Subgroup Analysis of the Primary Efficacy Outcome in the Primary Analysis Population

eFigure 2. The Restricted Cubic Spline Curve According to the Treatment Group

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable 1. Inclusion and Exclusion Criteria

Inclusion criteria

1. Age ≥ 20 years

2. Patients who underwent EVT for acute cerebral infarction with large cerebrovascular occlusion (ICA, MCA, M1 or M2, BA, VA, ACA, A1, or PCA, P1)

3. Patients with successful cerebral artery reopening after intraarterial reopening (modified Treatment In Cerebral Infarction score, mTICI 2b or mTICI 3)

4. Patients with elevated BP (systolic BP \geq 140 mmHg) on at least two measurements with a two-minute interval within 2 hours of successful recanalization.

Exclusion criteria

1. Age <20 years

2. Patients whose BP is less than 140 mmHg after successful recanalization through IAT

3. Patients with contraindications for use of antihypertensive medication

4. Patients with symptomatic ICH before participating in the study after the successful arterial reopening

5. Patients with impaired pre-disease neurological function (modified Rankin Scale, mRS >2)

6. Serious medical or surgical illness

7. Patients who are deemed hard to recruit for the study by the investigators.

8. Patients who did not agree to participate in this study

9. Patients who participated in a study that did not allow duplicate participation

Abbreviation: EVT, endovascular thrombectomy; ICA, internal carotid artery; MCA, middle

cerebral artery; BA, basilar artery; VA, vertebral artery; ACA, anterior cerebral artery; PCA,

posterior cerebral artery; BP, blood pressure; ICH, intracerebral hemorrhage.

	Intensive management Conventional manager		
Characteristics	(N=155)	(N=150)	
Demographics			
Age, mean (SD), y	73.2 (12.1)	72.9 (10.8)	
Sex, No. (%)			
Female	63 (40.6)	60 (40.0)	
Male	92 (59.4)	90 (60.0)	
Medical history, No. (%)			
Hypertension	121 (78.1)	113 (75.3)	
Atrial fibrillation	77 (49.7)	71 (47.3)	
Diabetes mellitus	65 (41.9)	65 (43.3)	
Hyperlipidemia	61 (39.4)	56 (37.3)	
Smoking	39 (25.2)	29 (19.3)	
Previous stroke	36 (23.2)	31 (20.7)	
CAOD	18 (11.6)	16 (10.7)	
Active cancer	9 (5.8)	5 (3.3)	
Congestive heart failure	7 (4.5)	7 (4.7)	
PAOD	2 (1.3)	6 (4.0)	
NIHSS score just before EVT ^a	13 (6)	13 (7)	
0-5	14 (9.0)	18 (12.0)	
6-15	83 (53.5)	81 (54.0)	
≥16	58 (37.4)	51 (34.0)	
Intravenous tissue-type plasminogen activator	44 (28.4)	55 (36.7)	
TOAST classification, No. (%) ^b			
Cardioembolism	76 (49.0)	78 (52.0)	
Large artery atherosclerosis	41 (26.5)	43 (28.7)	
Stroke of other determined etiology	4 (2.6)	1 (0.7)	
Undetermined, negative evaluation	21 (13.5)	23 (15.3)	
Undetermined, two or more causes identified	13 (8.4)	5 (3.3)	
Time parameters			
Onset to puncture time, median (IQR),	388.0 (223.5, 692.5)	356.0 (208.0, 730.0)	
Puncture to reperfusion time, median (IQR),	30.0 (22.0, 47.0)	31.5 (20.0, 48.0)	
Onset to reperfusion time, median (IQR), minutes	421.0 (265.5, 772.0)	395.5 (253.0, 764.0)	
Onset to randomization time, median (IQR), minutes	495.0 (327.5, 825.0)	472.5 (315.0, 820.0)	

eTable 2. Demographic and Clinical Characteristics in Intention-to-Treat Analysis

 $\ensuremath{\mathbb{C}}$ 2023 American Medical Association. All rights reserved.

Abbreviation: CAOD, coronary artery obstructive disease; PAOD, peripheral artery occlusive disease; NIHSS, National Institute of Health Stroke Scale; EVT, endovascular thrombectomy; TOAST classification, Trial of ORG 10172 in Acute Stroke Treatment classification.

^aThe NIHSS score ranges between 0 and 42, where a score of 0 signifies no symptoms (best outcome), and a score of 42 represents a state of coma (worst outcome).

^bThe TOAST classifications were determined based on a consensus of stroke neurologists in each participating hospital.

	Intensive management	Conventional management	P value
	(N=155)	(N=150)	
BP parameters			
SBP at enrollment, mean (SD), mmHg	155.2 (13.4)	154.8 (14.4)	.80
DBP at enrollment, mean (SD), mmHg	83.9 (14.4)	85.4 (14.1)	.38
SBP at 1h, mean (SD), mmHg	135.1 (19.9)	140.6 (19.5)	.02
DBP at 1h, mean (SD), mmHg	77.8 (16.1)	80.3 (15.3)	.17
SBP at 24 h, mean (SD), mmHg	128.5 (16.3)	137.1 (19.9)	<.001
DBP at 24 h, mean (SD), mmHg	70.7 (12.7)	75.1 (11.6)	.002
Mean SBP over 24 h, mean (SD), mmHg	129.2 (7.7)	138.0 (13.6)	<.001
Mean DBP over 24 h, mean (SD), mmHg	72.0 (8.1)	77.0 (9.9)	<.001
Time in target SBP range (%)			
SBP <140 mmHg, mean (SD)	83.0 (15.3)	54.2 (32.2)	<.001
SBP 140-180 mmHg, mean (SD)	14.2 (13.5)	42.1 (30.4)	<.001
SBP <180 mmHg, mean (SD)	99.6 (1.5)	99.1 (3.1)	.07
SBP out of range, No. (%)			
SBP exceeding >180 mmHg at least once	6 (3.9)	14 (9.3)	.09
SBP exceeding >200 mmHg at least once	2 (1.3)	1 (0.7)	>.999
SBP dropping <100 mmHg at least once	46 (29.7)	26 (17.3)	.02
Intravenous BP medication, No. (%)	115 (74.2)	28 (18.7)	<.001
Nicardipine	107 (69.0)	28 (18.7)	<.001
Labetalol	10 (6.5)	0 (0.0)	.004

eTable 3. Changes of Blood Pressure Between Groups

Abbreviation: BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure.

eTable 4. Primary and Secondary Outcomes in Per-Protocol Analysis

	Intensive management (n = 148)	Conventional management $(n = 140)$	Risk difference (95% CI)	Unadjusted OR (95% CI)	Adjusted OR ^a (95% CI)	p-value
Primary efficacy outcome						
Favorable independence at 3 months (mRS score 0-2)	59/148 (39.8)	80/140 (57.1)	-17.3 (-28.7 to -5.9)	0.50 (0.31 to 0.80)	0.52 (0.30 to 0.90)	.02
Primary Safety outcomes						
Symptomatic intracerebral hemorrhage	12/148 (8.1)	11/140 (7.9)	0.3 (-6.0 to 6.5)	1.04 (0.44 to 2.43)	0.96 (0.40 to 2.32)	.93
Death related to the index stroke within 3 months	12/148 (8.1)	7/140 (5.0)	3.1 (-2.6 to 8.8)	1.68 (0.64 to 4.39)	1.65 (0.57 to 4.82)	.36
Secondary outcomes						
mRS score reduction (shift analysis)				0.55 (0.36 to 0.83)	0.62 (0.41 to 0.95)	.03
NIHSS score at 24 hours, mean (SD)	11.32 (7.20)	9.01 (6.99)		2.23 (0.58 to 3.88)	1.06 (-0.13 to 2.30) ^b	.08
Excellent recovery of NIHSS score at 24 hours ^c	23/146 (15.8)	36/140 (25.7)	-1.0 (-19.3 to 0.6)	0.54 (0.30 to 0.97)	0.60 (0.33 to 1.10)	.10
Successful reperfusion at 24 hours ^d	126/140 (90)	127 /135 (94.1)	-4.1 (-10.4 to 2.3)	0.57 (0.23 to 1.40)	0.60 (0.23 to 1.54)	.29
Favorable independence at 1 month (mRS score 0-2)	54/143 (37.8)	71/137 (51.9)	-4.1 (-25.6 to -2.5)	0.56 (0.35 to 0.91)	0.64 (0.37 to 1.10)	.11
Euro-QoL score, mean (SD)	0.51 (0.43)	0.64 (0.39)		-0.13 (-0.22 to -0.03)	-0.09 (-0.17 to -0.01) ^b	.04
Malignant cerebral edema ^e	10/148 (6.7)	2/140 (1.4)	5.3 (0.8-9.8)	5.00 (1.08 to 23.24)	6.01 (1.19 to 30.27)	.03

 $\ensuremath{\mathbb C}$ 2023 American Medical Association. All rights reserved.

Abbreviation: EQ-5D-3L, EuroQoL 5-Dimension Self-Report Questionnaire; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; OR, odds ratio.

^aAdjusted for age, sex, onset to randomization time, and the NIHSS score just before endovascular thrombectomy.

^bAnalyzed with linear regression adjusted for age, sex, onset to randomization time, and the NIHSS score just before endovascular thrombectomy.

^cIndicates as NIHSS score 0-1 or improvement more than 8.

^dSuccessful reperfusion at 24 hours was determined by a modified Treatment In Cerebral Infarction score \geq 2b using MR angiography or CT angiography at 24 hours.

^eMalignant cerebral edema refers to a condition characterized by rapid neurological deterioration accompanied by substantial brain swelling in CT or MRI, which often leads to death or poor functional outcomes.

	Intensive management (N=155)	Conventional management (N=150)	P value
Occlusion site	· · ·		
ICA	34 (21.9)	32 (21.3)	>.999
MCA	108 (69.7)	101 (67.3)	.75
ACA	1 (0.6)	3 (2.0)	.59
BA	12 (7.7)	12 (8.0)	>.999
VA	4 (2.6)	3 (2.0)	>.999
PCA	0 (0.0)	1 (0.7)	.99
ASPECTS, median (IQR)	9.0 (7.0-10.0)	9.0 (8.0-10.0)	.34
ASPECTS category			.51
0-5	10 (6.6)	7 (4.7)	
6-8	56 (36.8)	49 (32.7)	
9-10	86 (56.6)	94 (62.7)	
Collateral grade ^a			.17
Good collateral (2-3)	102 (70.8)	90 (62.5)	
Poor collateral (0-1)	43 (29.2)	54 (37.5)	
Reocclusion	19 (12.3)	8 (5.3)	.05
mTICI immediate			.69
2b	34 (21.9)	34 (22.7)	
2c	18 (11.6)	22 (14.7)	
3	103 (66.5)	94 (62.7)	
mTICI at 24 hours		. ,	.57
0	11 (7.1)	7 (4.7)	
1	1 (0.6)	0 (0.0)	
2a	3 (1.9)	2 (1.3)	
2b	10 (6.5)	14 (9.3)	
2c	0 (0.0)	2 (1.3)	
3	121 (78.1)	116 (77.3)	
Any intracerebral hemorrhage	83 (53.5)	78 (52.3)	.93
Hemorrhagic transformation			.95
None	77 (49.7)	77 (51.3)	
HI1	27 (17.4)	24 (16.0)	
HI2	17 (11.0)	19 (12.7)	
PH1	17 (11.0)	13 (8.7)	
PH2	17 (11.0)	17 (11.3)	
Infarction volumes, median (IQR), ml ^b Infarction volumes, mean (SD), ml ^b	18.6 (6.7-62.6) 60.8 (91.6)	17.1 (5.4-40.9) 42.1 (73.9)	.11 .05

eTable 5. Imaging Findings

 $\ensuremath{\mathbb{C}}$ 2023 American Medical Association. All rights reserved.

Abbreviation: ICA, internal carotid artery; MCA, middle cerebral artery; ACA, anterior cerebral artery; BA, basilar artery; PCA, posterior cerebral artery; VA, vertebral artery; ASPECTS, Alberta Stroke Program Early CT Score; mTICI, modified Treatment In Cerebral Infarction score; HI, hemorrhagic infarction; PH, parenchymal hematoma.

^aCollateral grade was determined using the Tan scale.

^bInfarction volume was measured primarily using diffusion-weighted image. In cases where diffusion-weighted image was unavailable, fluid-attenuated inversion recovery image or CT scan were used instead.

	Unadjusted OR	Adjusted OR ^a	<i>P</i> value
	(95% CI)	(95% CI)	
Primary efficacy outcome			
Functional independence at 3 months (mRS score 0-2)	0.54 (0.41 to 0.72)	0.56 (0.43 to 0.72)	<.001
Primary Safety outcome			
Symptomatic intracerebral hemorrhage	1.14 (0.51 to 2.52)	1.10 (0.48 to 2.53)	.82
Death related to the index stroke within 3 months	1.49 (0.72 to 3.10)	1.73 (0.65 to 4.59)	.28
Secondary outcome			
mRS score reduction (shift analysis)	0.59 (0.45 to 0.78)	0.65 (0.50 to 0.84)	.001
NIHSS score at 24 hours	2.00 (0.33 to 3.66)	1.05 (-0.17 to 2.27) ^b	.09
Excellent recovery of NIHSS score at 24 hours ^c	0.59 (0.34 to 1.02)	0.63 (0.35 to 1.12)	.12
Successful reperfusion at 24 hours ^d	0.65 (0.23 to 1.81)	0.65 (0.25 to 1.72)	.39
Functional independence at 1 month (mRS score 0-2)	0.60 (0.44 to 0.81)	0.65 (0.49 to 0.87)	.003
EQ-5D-3L score	-0.12 (-0.21 to - 0.02)	-0.08 (-0.16 to - 0.01) ^b	.04
Malignant cerebral edema ^e	6.16 (1.79 to 21.23)	8.05 (2.80-23.19)	<.001

eTable 6. Post Hoc Sensitivity Analysis Considering Enrollment Site

Abbreviation: EQ-5D-3L, EuroQoL 5-Dimension Self-Report Questionnaire; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; OR, odds ratio.

^aAdjusted for age, sex, onset to randomization time, and the NIHSS score just before

endovascular thrombectomy.

^bAnalyzed with linear regression adjusted for age, sex, onset to randomization time, and the NIHSS score just before endovascular thrombectomy.

^cIndicates as NIHSS score 0-1 or improvement more than 8.

^dSuccessful reperfusion at 24 hours was determined by a modified Treatment In Cerebral

Infarction score \geq 2b using MR angiography or CT angiography at 24 hours.

^eMalignant cerebral edema refers to a condition characterized by rapid neurological

deterioration accompanied by substantial brain swelling in CT or MRI, which often leads to death or poor functional outcomes.

eFigure 1. Prespecified Subgroup Analyses of the Primary Efficacy Outcome in the

Primary Analysis Population

There were no significant interactions observed in any predetermined subgroup with favorable outcomes. The intensive management was associated with unfavorable outcomes across all strata.

No. of patients		ts	Adjusted common	Conventional management	Intensive management better	P value for Interaction
Variable Intensive	Intensive	Conventional odds ratio (95%Cl)	better			
Overall	155	147	0.56 (0.33 to 0.96)	-8-		
Age, y						
<65	34/155	34/150	0.61 (0.34 to 1.12)		1 4 10 1	74
065	121/155	116/150	0.53 (0.17 to 1.63)			./1
Sex						
Female	63/155	60/150	0.43 (0.17 to 1.13)		1 	
Male	92/155	90/150	0.69 (0.36 to 1.33)			.39
Hypertension						
Yes	121/155	113/150	0.55 (0.29 to 1.02)			05
No	34/155	37/150	0.63 (0.20 to 1.96)			.90
Diabetes						
Yes	65/155	65/150	0.49 (0.20 to 1.21)			
No	90/155	85/150	0.55 (0.27 to 1.10)		1 <u>1</u>	.95
Atrail fibrillation			· · ·			
Yes	77/155	71/150	0.40 (0.16 to 1.00)			
No	78/155	79/150	0.62 (0.31 to 1.25)			.75
NIHSS score						
0237	67/155	58/150	0.45 (0.16 to 1.26)		: ;	
<15	88/155	92/150	0.67 (0.35 to 1.31)			.55
Onset to puncture time, h						
08	75/155	78/150	0.57 (0.26 to 1.21)		1 1 1 	
>6	80/155	72/150	0.52 (0.23 to 1.20)		1	./6
Occlusion site						
ICA	34/155	32/150	0.25 (0.07 to 0.90)			
MCA	47/155	49/150	0.59 (0.32 to 1.11)			NA
ASPECTS			· · ·			
ASPECTS 6-8	56/152	49/150	0.58 (0.22 to 1.51)			
ASPECTS 9-10	86/152	94/150	0.60 (0.30 to 1.20)			.99
Collateral grade			· · · · ·			
Good	102/144	90/144	0.47 (0.24 to 0.92)			
Poor	42/144	54/144	0.54 (0.17 to 1.71)		· · · · · · · · · · · · · · · · · · ·	.54
TICI immediate			· · ·			
2b or 2c	52/155	56/150	0.68 (0.28 to 1.68)			~
3	103/155	94/155	0.51 (0.26 to 1.00)			.60
				0.01 0.1	i 10	

eFigure 2. The Restricted Cubic Spline Curve According to the Treatment Group

Panel A, intensive management exhibited a reverse J-shape correlation between the mean 24hour SBP and dependent or dead outcome, indicating a significant association between lower the mean 24-hour SBP and worse outcomes. Panel B, the conventional management demonstrated a linear correlation between the mean 24-hour SBP and dependent or dead outcome, suggesting that higher the mean 24-hour BP was associated with worse outcomes.



© 2023 American Medical Association. All rights reserved.